TickerFacts.

Myriad Genetics Inc (MYGN): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2017-06-30 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

-$333.50M
Year ended 2025-12-31
-$48.40M
Trailing 12 months to 2026-06-30
$288.20M2009-06-30: $135.91M2010-06-30: $142.16M2011-06-30: $165.00M2012-06-30: $189.39M2013-06-30: $236.90M2014-06-30: $288.20M2015-06-30: $158.60M2016-06-30: $180.20M2017-06-30: $92.30M2018-06-30: $176.30M2019-06-30: $80.60M2021-12-31: -$127.70M2022-12-31: -$87.90M2023-12-31: -$195.50M2024-12-31: -$62.30M2025-12-31: -$333.50M-$333.50M
2009-06-30 EBITDA (USD) 2025-12-31
Period endedEBITDAChange YoYSource filing
2025-12-31-$333.50Mn/m2026-02-24, From 2025-01-01
2024-12-31-$62.30Mn/m2026-02-24, From 2024-01-01
2023-12-31-$195.50Mn/m2026-02-24, From 2023-01-01
2022-12-31-$87.90Mn/m2025-02-28, From 2022-01-01
2021-12-31-$127.70Mn/a2024-02-28, From 2021-01-01
No annual figure between 2019-06-30 and 2021-12-31.
2019-06-30$80.60M-54.3%2022-02-25, From 2018-07-01
2018-06-30$176.30M+91.0%2020-08-13, From 2017-07-01
2017-06-30$92.30Mn/c2019-08-13, From 2016-07-01
2016-06-30$180.20M+13.6%2018-08-24, From 2015-07-01
2015-06-30$158.60M-45.0%2018-08-24, From 2014-07-01
2014-06-30$288.20M+21.7%2016-08-10, From 2013-07-01
2013-06-30$236.90M+25.1%2015-08-12, From 2012-07-01
2012-06-30$189.39M+14.8%2014-08-13, From 2011-07-01
2011-06-30$165.00M+16.1%2013-08-14, From 2010-07-01
2010-06-30$142.16M+4.6%2012-08-15, From 2009-07-01
2009-06-30$135.91Mn/a2011-08-15, From 2008-07-01

EBITDA at similar companies

Companies with the same SEC industry code (In Vitro & In Vivo Diagnostic Substances), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEBITDAChange YoY
Myriad Genetics Inc (MYGN)2025-12-31-$333.50Mn/m
Neogen Corp (NEOG)2026-05-31$94.70Mn/m
Lantheus Holdings, Inc. (LNTH)2025-12-31$380.93M-27.0%
QuidelOrtho Corp (QDEL)2025-12-28-$477.20Mn/m
Idexx Laboratories Inc (IDXX)2025-12-31$1.51B+19.6%
Intellia Therapeutics, Inc. (NTLA)2025-12-31-$431.22Mn/m
Alpha Teknova, Inc. (TKNO)2025-12-31-$10.63Mn/m
Immucell Corp (ICCC)2025-12-31$4.43M+306.8%
Aspira Women's Health Inc. (AWHL)2025-12-31-$7.80Mn/m

Compare MYGN, NEOG, LNTH, QDEL side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗